Plain-English translation of NCT04128189 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing , a vaccine that protects against shingles, in people with kidney failure and kidney transplant recipients. Because kidney disease and transplant medicines weaken the immune system, these patients face higher risks of developing shingles and serious complications. Researchers want to know if this vaccine works well in this population and whether a booster dose after transplant might help.
People with kidney failure and transplant recipients have weakened immune systems that make them vulnerable to shingles and painful complications. While this medication is recommended for immunocompromised patients, doctors don't yet know the best timing or whether booster doses would help protect transplant recipients long-term.
You likely qualify if…
You likely don't qualify if…
You will receive two doses of the vaccine given several months apart, with blood tests to measure your immune response. If you undergo kidney transplant during the study, you will be randomly assigned either to receive a third booster dose of the vaccine after transplant or to not receive a booster, and researchers will track your immune response and any side effects over time. You'll have regular study visits and blood draws to monitor how well the vaccine is working.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States